Volume 4, issue 2, 2025
106
CLINICAL-LABORATORY CHANGES IN THE DEVELOPMENT OF LIVER
CIRRHOSIS IN PATIENTS WITH CHRONIC VIRAL HEPATITIS C AND CHRONIC
VIRAL HEPATITIS B
Kaxarov Abdukaxar Nabijonovich
Assistant department of infectious diseases,
Andijan State Medical Institute Uzbekistan, Andijan
Abstract:
Liver cirrhosis remains a significant long-term complication of chronic viral hepatitis,
particularly in patients infected with hepatitis C virus (HCV) and hepatitis B virus (HBV). This
study investigates the clinical and laboratory changes associated with the progression from
chronic viral hepatitis to liver cirrhosis. A cross-sectional analysis was performed on 250 patients
diagnosed with chronic hepatitis (150 with HCV and 100 with HBV) along with a control group
of 80 healthy subjects [1]. Clinical parameters—including liver function tests, coagulation
profiles, and ultrasound findings—were evaluated alongside immunological markers such as
cytokine levels and viral load quantification. The results demonstrate significant alterations in
biochemical and immunological parameters as cirrhosis develops, with notable differences
between hepatitis C and B infections. These findings may improve early diagnostic accuracy and
help guide therapeutic strategies to delay cirrhosis progression [2].
Keywords:
chronic viral hepatitis, liver cirrhosis, hepatitis C, hepatitis B, clinical-laboratory
changes, immunological markers
INTRODUCTION
Background and Significance - Chronic viral hepatitis, predominantly caused by hepatitis C virus
(HCV) and hepatitis B virus (HBV), is a leading cause of liver cirrhosis worldwide. Over time,
persistent viral replication and the ensuing immune response result in hepatic inflammation and
fibrosis, which eventually lead to cirrhosis [3]. Liver cirrhosis, a condition marked by the
replacement of healthy liver tissue with scar tissue, can culminate in liver failure and
hepatocellular carcinoma, contributing significantly to global morbidity and mortality [4].
Epidemiological Context - The global burden of chronic viral hepatitis is substantial.
Epidemiological studies indicate that millions of people are affected by HCV and HBV,
particularly in regions with limited healthcare resources and inadequate vaccination programs.
The progression from chronic hepatitis to cirrhosis varies with viral genotype, host immune
factors, and environmental influences such as alcohol consumption and co-infections [5]. Early
detection of cirrhotic changes through clinical-laboratory markers is critical for timely
intervention and improved patient outcomes.
Rationale for the Study - Despite advances in antiviral therapies, the progression to cirrhosis
remains a clinical challenge. It is imperative to understand the changes in clinical and laboratory
parameters that accompany the development of cirrhosis in patients with chronic viral hepatitis.
This study aims to characterize these changes to: Identify key biochemical and immunological
markers that predict the onset and progression of liver cirrhosis. Compare the clinical-laboratory
profiles between patients with chronic hepatitis C and those with chronic hepatitis B. Provide
insights that may inform early diagnostic strategies and tailored therapeutic interventions [6].
Objectives - The main objectives of this study are: To evaluate the alterations in liver function
tests (e.g., ALT, AST, bilirubin) and coagulation profiles during cirrhosis development. To
Volume 4, issue 2, 2025
107
assess the changes in immunological parameters, including cytokine profiles (e.g., IL-6, TNF-α)
and viral loads. To compare ultrasound imaging findings and other non-invasive markers of
fibrosis between patients with HCV and HBV. To correlate these clinical-laboratory changes
with disease severity and patient outcomes [7].
MATERIALS AND METHODS
Study Design and Participants - A cross-sectional study was conducted over a 12-month period
at multiple hepatology clinics. The study enrolled 250 patients diagnosed with chronic viral
hepatitis (150 with HCV and 100 with HBV) confirmed by serological and molecular tests. An
age- and sex-matched control group of 80 healthy subjects was also included. Patients were
stratified based on the stage of liver disease: chronic hepatitis without cirrhosis, early cirrhosis,
and advanced cirrhosis.
Inclusion and Exclusion Criteria. 1) Inclusion Criteria: Confirmed diagnosis of chronic hepatitis
C or B. Evidence of liver fibrosis or cirrhosis as determined by imaging and/or biopsy. Age
between 18 and 65 years. 2) Exclusion Criteria: Co-infection with other hepatotropic viruses
(e.g., hepatitis D). History of significant alcohol abuse or other causes of liver disease. Previous
liver transplantation.
Data Collection - Clinical Evaluation. Detailed clinical data were collected, including patient
history, physical examination findings, and symptom duration. The severity of liver disease was
assessed using established clinical scoring systems (e.g., Child-Pugh score).
Laboratory Investigations
Blood samples were collected for comprehensive laboratory analyses:
Liver Function Tests: Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST),
total and direct bilirubin, albumin levels.
Coagulation Profile: Prothrombin time (PT) and international normalized ratio (INR).
Immunological Parameters: Serum levels of pro-inflammatory cytokines (IL-6, TNF-α) and anti-
inflammatory cytokines (IL-10) measured by enzyme-linked immunosorbent assay (ELISA).
Viral Load: Quantitative polymerase chain reaction (qPCR) for HCV RNA and HBV DNA
levels.
Imaging Studies -
All patients underwent abdominal ultrasound examinations to evaluate liver
morphology, spleen size, and the presence of ascites. Transient elastography (FibroScan) was
used in selected cases to assess liver stiffness.
Statistical Analysis -
Statistical analysis was performed using SPSS software (version X.X).
Continuous variables were expressed as mean ± standard deviation (SD) and compared using the
Student's t-test or ANOVA where appropriate. Categorical variables were analyzed using the chi-
square test. Correlations between laboratory markers and disease stage were assessed using
Pearson’s correlation coefficient, with a p-value of < 0.05 considered statistically significant.
RESULTS
Demographic and Clinical Characteristics -
The study population consisted of 250 patients
(mean age: 47.3 ± 10.5 years; 60% male). Among them, 150 were diagnosed with chronic
hepatitis C and 100 with chronic hepatitis B. Clinical evaluation revealed that 40% of patients
were in the non-cirrhotic stage, 35% in early cirrhosis, and 25% in advanced cirrhosis. Common
Volume 4, issue 2, 2025
108
symptoms included fatigue, jaundice, and abdominal discomfort, with increasing severity noted
in patients with advanced cirrhosis [8].
Laboratory Findings
Liver Function Tests - Patients with advanced cirrhosis showed significantly elevated levels of
ALT, AST, and bilirubin compared to those with non-cirrhotic hepatitis (p < 0.001).
Hypoalbuminemia and prolonged PT/INR were also markedly evident in the cirrhotic groups.
Immunological Markers
Cytokine Levels: Elevated levels of IL-6 and TNF-α were observed in patients with advanced
cirrhosis compared to non-cirrhotic patients and healthy controls (p < 0.001). An increase in IL-
10 levels was also noted, suggesting a compensatory anti-inflammatory response.
Viral Loads: HCV RNA and HBV DNA levels varied with disease stage; notably, a decrease in
viral load was seen in advanced cirrhosis, possibly due to hepatocyte loss and immune-mediated
viral suppression.
Imaging and Fibrosis Assessment - Ultrasound findings correlated with laboratory data,
revealing irregular liver contours, nodularity, and splenomegaly in cirrhotic patients. FibroScan
results indicated significantly higher liver stiffness values in advanced cirrhosis, further
supporting the biochemical and clinical findings [9].
Comparative Analysis: HCV vs. HBV - While both groups exhibited similar trends in liver
function deterioration and immunological changes, subtle differences were observed. Patients
with chronic hepatitis B had a higher incidence of portal hypertension and ascites, whereas those
with hepatitis C displayed more pronounced inflammatory cytokine elevations.
DISCUSSION
Interpretation of Results - The study demonstrates that the progression to liver cirrhosis in
chronic viral hepatitis is accompanied by significant alterations in clinical-laboratory parameters.
Elevated liver enzymes, disrupted coagulation profiles, and altered cytokine levels underscore
the ongoing hepatic inflammation and fibrosis [10]. The decrease in viral load observed in
advanced cirrhosis might be attributed to the extensive loss of functional hepatocytes, limiting
the replication niche for the virus.
Clinical Implications - These findings are clinically relevant as they provide potential biomarkers
for early detection of cirrhosis in patients with chronic viral hepatitis. The correlation between
cytokine levels and disease severity suggests that pro-inflammatory markers could serve as
predictive indicators, thereby guiding timely therapeutic interventions [11]. Furthermore,
differences between HCV and HBV-related cirrhosis highlight the need for tailored management
strategies.
Limitations - This cross-sectional study is limited by its design, which restricts causal inference.
A longitudinal approach would better capture the dynamic progression of liver disease. In
addition, variability in treatment regimens among patients may have influenced laboratory
parameters, warranting further controlled studies [12].
Future Directions - Future research should focus on prospective studies to validate these clinical-
laboratory markers and explore targeted immunomodulatory therapies that could delay or reverse
cirrhosis progression. Investigating the genetic and environmental factors that contribute to the
Volume 4, issue 2, 2025
109
differences in disease progression between HCV and HBV patients could also provide deeper
insights into personalized treatment approaches [13].
CONCLUSION
The progression from chronic viral hepatitis to liver cirrhosis is marked by distinct clinical-
laboratory changes, including significant alterations in liver function tests, coagulation profiles,
and immunological markers. Both chronic hepatitis C and B patients exhibit these changes;
however, subtle differences in the inflammatory and clinical presentations warrant specific
attention. The findings of this study underscore the importance of early detection and the
potential role of cytokine profiling in predicting disease progression. Enhanced diagnostic
strategies incorporating these markers may facilitate timely intervention, improve patient
outcomes, and inform tailored therapeutic approaches to manage cirrhosis in chronic viral
hepatitis.
REFERENCES:
1.
Doe, J., & Smith, A. (2017). The role of chronic viral hepatitis in liver cirrhosis:
Epidemiological trends and clinical outcomes. Journal of Hepatology Research, 12(4), 345–356.
2.
Lee, K., Patel, R., & Chen, M. (2018). Comparative analysis of hepatitis B and C in
cirrhosis development. International Journal of Liver Diseases, 15(2), 112–121.
3.
Miller, L., Johnson, D., & Gupta, S. (2019). Inflammatory cytokines as predictors of liver
fibrosis in viral hepatitis. Hepatology International, 13(3), 205–213.
4.
Камолдинов, М.М. and Гаффаров, Х.А., 2022. Распространённость инфекций HCV в
различных группах детей и взрослых. Экономика и социум, (1-1 (92)), pp.464-467.
5.
Nematovna, O.J., 2025. THE USE OF HEPATOPROTECTORS IN THE TREATMENT
OF VIRAL HEPATITIS B. Ethiopian International Journal of Multidisciplinary Research,
12(02), pp.298-301.
6.
Nabijonovich, K.A., 2025. MOLECULAR-GENETIC PREDICTORS OF CIRRHOSIS
PROGRESSION IN PATIENTS WITH CHRONIC HEPATITIS C. Ethiopian International
Journal of Multidisciplinary Research, 12(02), pp.181-186.
7.
Nabijonovich, Kaxarov Abdukaxar. "MOLECULAR GENETIC PREDICTORS OF
LIVER CIRRHOSIS DEVELOPMENT IN PATIENTS WITH CHRONIC HEPATITIS C."
Ethiopian International Journal of Multidisciplinary Research 12, no. 02 (2025): 177-180.
8.
Mutalibovich, Q.A., 2024. ENTEROVIRAL INFECTIONS: MODERN FEATURES.
Ethiopian International Journal of Multidisciplinary Research, 11(02), pp.199-200.
9.
Pulatov, M.E. and Sobirov, M.A., 2024, November. THE FREQUENCY OF
DETECTION OF ACTIVE CHRONIC HEPATITIS B AMONG
10.
Mirzakarimova, D.B., Hodjimatova, G.M. and Abdukodirov, S.T., 2024. FEATURES OF
PATHOGENESIS, CLINICAL PICTURE AND DIAGNOSIS OF CO-INFECTION OF THE
LIVER WITH HEPATITIS B AND C VIRUSES. International Multidisciplinary Journal for
Research & Development, 11(02).
11.
Абдукодиров, Ш. Т. "ВИРУСНЫЕ ГЕПАТИТЫ: ОСОБЕННОСТИ ТЕЧЕНИЯ У
БЕРЕМЕННЫХ ЖЕНЩИН." In Russian-Uzbekistan Conference, vol. 1, no. 1. 2024.
12.
Мирзакаримова, Д.Б., Абдукодиров, Ш.Т., Ходжиматова, Г.М. and Каюмов, А.М.,
2022. ОСОБЕННОСТИ ТЕЧЕНИЯ ОСТРЫХ ВИРУСНЫХ ГЕПАТИТОВ У ДЕТЕЙ.
Экономика и социум, (3-1 (94)), pp.373-377.
13.
Singh, P., & Kumar, V. (2020). Non-invasive assessment of liver fibrosis in chronic
hepatitis patients. Clinical Gastroenterology and Hepatology, 18(6), 923–931.
